Cipan increases investment in Vila Franca de Xira with a new antibiotic

Cipan – Companhia Industrial Productora de Antibioticos will exclusively supply the raw material for a new antibiotic that will be launched, in the first quarter of 2019, in the United States. Approved in October by the US authorities, “Nuzyra” is based on omadicicline, which will be produced in the Portuguese industry installed 55 years ago in the Carregado Vala, north of the municipality of Vila Franca de Xira.

To develop this production, Cipan will invest about six million euros in its own unit, a figure that joins the eight million already invested in the factory in the last two years by the Spanish group SUANFARMA, which acquired Cipan in 2016. The Portuguese company, specialized in the manufacture and marketing of active pharmaceutical ingredients, mainly antibiotics, but also other raw materials, is undergoing a growth phase. In 2017 it had a turnover of 19.2 million euros, 7.6 million more than the previous year. And it plans to reach 25 million by 2018.

Héctor Ara, president of the SUANFARMA group, makes a positive assessment  on the acquisition of the Portuguese company, stressing that it has accumulated know-how and is one of the few in the world that has the conditions to produce, simultaneously, pharmaceutical compounds by fermentation and by chemical synthesis. Héctor Aras told PÚBLICO that it is SUANFARMA’s intention to transfer its research center, currently in Barcelona, ​​to Cipan’s facilities.

Read more in source: Publico

Read More

Cipan has investments of 14 million

Cipan, Vala do Carregado’s antibiotic-producing company, is benefiting from investments of around 14 million euros. Acquired two years ago by the Spanish group SUANFARMA, the Companhia Industrial Produtora de Antibioticos, created 55 years ago, doubled its number of employees and recorded a large increase in turnover. The company, which received a visit from local authorities and journalists, is preparing to start an investment of 6 million euros in a new unit aimed at the production of Omadacycline. It is a new active ingredient that Cipan will provide exclusively to a US company that has recently been able to validate a new antibiotic, which will be launched in 2019.

In the last two years, the Spanish group has already invested another 8 million euros in the modernization of Cipan’s facilities and in the construction of a new water treatment plant. The Portuguese company, specialized in the manufacture and commercialization of active pharmaceutical ingredients, mainly antibiotics, but also other raw materials, is going through a phase of great growth. It registered in 2017 a turnover of 19, 262 million euros, plus 7, 6 million of the previous year. And it intends to reach a turnover of 25 million euros already in 2018. Héctor Ara, president of the SUANFARMA group, makes a very positive balance on the acquisition of the Portuguese company, emphasizing that it has a lot of accumulated know-how and that it is one of the few industries in the world that has the conditions to produce, simultaneously, pharmaceutical compounds by fermentation and by chemical synthesis . He also pointed out that Cipan is using actually about the 30 percent of its capacity and that it can grow in the coming years. Alberto Mesquita, mayor of Vila Franca de Xira, congratulated the president of SUANFARMA and the Portuguese managers of Cipan for the development achieved by the company in recent years.

SOURCE: Voz Ribatejana

Read More

Corporate Event Notice

Delisting of shares

As of 28/09/2018, ordinary shares (ISIN PTCPN0AE0002) issued by CIPAN-IND.PRODUTOS ANTIBIOTIC.
will be delisted from EURONEXT ACCESS LISBON.

Reason: Decision of Euronext based on rule 5.2., 5 of Euronext Access Rule Book
Delisting date: 28/09/2018
Last trading date: 27/09/2018
Euronext Designation: CIPAN
ISIN code: PTCPN0AE0002 Euronext code: PTCPN0AE0002
Trading Symbol: CPN National code: CPN AE

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided “as is” based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator.

Read More

Cipan present at DCAT Week 2017

Together with Suanfarma, CIPAN will be present at DCAT Week, March 20-23, 2017. We will be glad to meet you at suite no.1903 at the Benjamin Hotel 125 E 50th St, New York.

The Drug, Chemical & Associated Technologies Association (DCAT) powers relationships and industry knowledge for companies engaged in the business of pharmaceutical development and manufacturing.

DCAT is a 501(c)6, not-for-profit, member-supported, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies.

Founded in 1890, DCAT has been providing a life-long collegial community for industry representatives for over 125 years.

Read More

Suanfarma acquires CIPAN, a public listed Portuguese company

Suanfarma has successfully completed the acquisition of CIPAN (Companhia Industrial Productora de Antibioticos), a prestigious internationally recognized company, pioneer in the production of Antibiotics. Cipan was founded in 1963 in Castanheira do Ribatejo, 30 km north of Lisbon. Their factory is FDA approved, has 800.000 liters of reaction capacity both in fermentation and chemical synthesis processes. Cipan is listed in the EASYNEXT index in Portugal, so Suanfarma has carried out an IPO for a 15% of the free float share capital of the company.

With this acquisition, the third one so far in 2016 following Distribuidora Disandalo in Colombia and Idifarma in Pamplona, Spain, Suanfarma has carried out the industrial investments planned for 2016 after the entry of its latest shareholder, ProA Capital, which acquired a stake in the company in October 2015. CIPAN completes the production of active pharmaceutical ingredients both biotechnological processes (fermentation) and chemical synthesis.

This way, the Spanish company, has significantly reinforced its industrial and development capabilities, and will be able to start the production of its own products on the antidiabetic and probiotic fields, which are currently in R&D phase.

Read More

Increasing Minocycline production

Cipan is increasing its production of Minocycline HCl in 2017. With a production capacity of 30 Ton/year, Cipan has produced small amounts of this product in the last few years. In 2017, we are significantly increasing the output of Minocycline HCl.

Minocycline is a tetracycline antibiotic and therefore fights bacterial infections  in the human body. Minocycline is used to treat many different bacterial infections, such as urinary tract infections, respiratory infections, but mainly skin infections.

Read More